Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Purchased by M&T Bank Corp

M&T Bank Corp raised its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 96,322 shares of the biopharmaceutical company’s stock after buying an additional 862 shares during the period. M&T Bank Corp owned approximately 0.07% of Halozyme Therapeutics worth $3,560,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of HALO. First Horizon Advisors Inc. boosted its position in shares of Halozyme Therapeutics by 24.5% in the 4th quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 293 shares during the period. Parkside Financial Bank & Trust acquired a new stake in shares of Halozyme Therapeutics during the fourth quarter valued at approximately $64,000. Headlands Technologies LLC lifted its position in shares of Halozyme Therapeutics by 1,068.2% in the 4th quarter. Headlands Technologies LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $65,000 after acquiring an additional 1,613 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt acquired a new position in Halozyme Therapeutics in the 4th quarter worth approximately $196,000. Finally, Cetera Trust Company N.A purchased a new position in Halozyme Therapeutics during the 4th quarter worth approximately $208,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Up 0.9 %

HALO stock opened at $41.21 on Wednesday. The firm has a market cap of $5.24 billion, a PE ratio of 19.53, a PEG ratio of 0.47 and a beta of 1.26. Halozyme Therapeutics, Inc. has a 1 year low of $29.85 and a 1 year high of $45.00. The company has a fifty day simple moving average of $40.04 and a 200 day simple moving average of $37.99. The company has a current ratio of 6.64, a quick ratio of 5.50 and a debt-to-equity ratio of 17.89.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The company had revenue of $230.04 million during the quarter, compared to analyst estimates of $235.25 million. Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. Sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 3.43 EPS for the current fiscal year.

Analyst Ratings Changes

HALO has been the subject of several recent analyst reports. TheStreet cut Halozyme Therapeutics from a “b-” rating to a “c+” rating in a research report on Monday, January 22nd. StockNews.com raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, February 23rd. The Goldman Sachs Group lowered their price objective on shares of Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating on the stock in a research report on Thursday, January 18th. HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Halozyme Therapeutics in a research note on Tuesday. Finally, Benchmark reaffirmed a “buy” rating and issued a $50.00 price target on shares of Halozyme Therapeutics in a research note on Tuesday, April 16th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $53.29.

Insider Activity

In other news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, April 17th. The stock was sold at an average price of $38.49, for a total value of $384,900.00. Following the transaction, the senior vice president now directly owns 168,176 shares in the company, valued at $6,473,094.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 30,000 shares of company stock valued at $1,196,800 over the last 90 days. 2.70% of the stock is currently owned by company insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.